CoChat
Sign Up
Cited by 33Blood Pressure and Hypertension StudiesCardiovascular Health and Disease PreventionSodium Intake and Health

Efficacy and safety of two treatment combinations of hypertension in very elderly patients

Fogari, Roberto, Zoppi, Annalisa, Mugellini, Amedeo, Corradi, Luca, Lazzari, Pierangelo, Preti, Paola, Derosa, Giuseppe·2009·Archives of Gerontology and Geriatrics
DOI 10.1016/j.archger.2008.03.012
Open this paper in CoChat — free account

Abstract

The study compared valsartan/amlodipine combination with irbesartan/hydrochlorothiazide (HCTZ) combination in very elderly hypertensives. After a 4-week placebo period, 94 hypertensives, aged 75-89 years were randomized to valsartan 160mg/amlodipine 5mg or irbesartan 300mg/HCTZ 12.5mg for 24 weeks according to a prospective, parallel group study. After 4 weeks amlodipine or HCTZ was doubled in non-responders. Patients were checked every 4 weeks. At each visit clinical sitting, lying and standing blood pressure (BP), systolic BP (SBP) and diastolic BP (DBP) were evaluated, and an electrocardiogram was performed. At the end of the placebo period and of the treatment period a non-invasive 24-h ambulatory BP monitoring (ABPM) was performed and electrolytes and uric acid were evaluated. Both combinations significantly reduced ambulatory BP. In the valsartan/amlodipine group the mean reduction (-29.9/-15.6 for 24h, -28.6/-14.5mmHg for day-time and -26.2/-17.4mmHg for night-time SBP/DBP) was similar to that of the irbesartan/HCTZ group (-29.6/-15.4 for 24h, -29.3/-14.9mmHg for day-time and -25.4/-16.9mmHg for night-time SBP/DBP). Both combinations significantly reduced clinical sitting and lying BP values with no difference between treatments. BP changes from lying to standing position were significantly greater in the irbesartan/HCTZ group (-17.2/-9.1mmHg) than in the valsartan/amlodipine group (-10.1/-1.9mmHg, p<0.05 for SBP and p<0.01 for DBP vs. irbesartan/HCTZ). Potassium significantly decreased and uric acid significantly increased (-0.4mmol/l, p<0.05 and +0.5mg/dl, p<0.05 vs. baseline, respectively) only in the irbesartan/HCTZ group. In conclusion, both combinations were similarly effective in reducing ambulatory and clinical BP in very elderly hypertensives. However, valsartan/amlodipine offered some advantages in terms of less pronounced BP orthostatic changes and absence of metabolic adverse effects.

Integrity signals

Registry

Crossref · 10.1016/j.archger.2008.03.012

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • ACE inhibitors, angiotensin receptor blockers, and calcium channel blockers are less likely to be associated with OH compared with beta-blockers and thiazide diuretics.

    “Angiotensin-converting enzyme inhibitors, angiotensin receptors blockers, and calcium channel blockers are less likely to be associated with OH compared with beta-blockers and thiazide diuretics. 315-318”

    From 2018 ESC Guidelines for the diagnosis and management of syncope (2018) · cites this paper as [318]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Fogari, R., Zoppi, A., Mugellini, A., Corradi, L., Lazzari, P., Preti, P., & Derosa, G.
Affiliations
University of Pavia (IT)
Corresponding author
Fogari, Roberto
ORCID
Venue
Archives of Gerontology and Geriatrics
Publisher
Elsevier BV
Published
2009-05
Volume
48
Issue
3
Pages
401-405
ISSN
0167-4943 (ISSN-L)
DOI
10.1016/j.archger.2008.03.012
OpenAlex
W2167653649
Cited by
33
References
44
Citations by year
2026: 1 · 2024: 1 · 2021: 1 · 2020: 2 · 2019: 1 · 2018: 6 · 2015: 2 · 2014: 1 · 2013: 1 · 2012: 4
FWCI
3.17
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Archives of Gerontology and Geriatrics (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
  • Health Sciences › Nursing › Nutrition and Dietetics › Sodium Intake and Health
Keywords
hypertension, very elderly patients, combination antihypertensive therapy, ambulatory blood pressure monitoring, orthostatic blood pressure response, potassium, uric acid, drug safety, treatment efficacy, renin-angiotensin system inhibitors, calcium channel blockers, thiazide diuretics
MeSH terms
Valsartan, Irbesartan, Aged, Aged, 80 and over, Analysis of Variance, Antihypertensive Agents, Biphenyl Compounds, Drug Therapy, Combination, Female, Humans, Hypertension, Male, Prospective Studies, Tetrazoles, Valine, Chi-Square Distribution, Treatment Outcome, Amlodipine, Blood Pressure Monitoring, Ambulatory

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review